In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly announces Guidant IPO for 20% of new company's stock

Executive Summary

Eli Lilly's device spin-off, Guidant Corp. (cardiac rhythm management, coronary artery disease intervention, minimally invasive surgery) has completed its IPO of 14.26 million shares at $14.50 per share, netting $192.5 million.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Financing
    • IPO
    • Spin-Off

Related Companies